Skip to content
DataLookout
Menu

IMVACSNCT06860178

Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

StatusActive, Not Recruiting
PhasePhase 4
SponsorEpicentre
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 7 more changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 33542 participants (planned 40000)
    • Primary completion date changed from estimate of May 2026 to Jul 30, 2026
    • Study completion date: Dec 2027 to Dec 26, 2027
    • Interventions: Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months (Other) to Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months (Other)
    • Secondary endpoints: details revised at 5 of 10 entries
    • Site details revised at 2 of 2 sites
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2025 to Jun 10, 2025
    • Site details revised at 2 of 2 sites
    v3
  3. Notable Start date: Apr 2025 to Jun 2025v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Malaria Incidence on 5-36 months at 12 months
Timeframe: from enrollment to 12 months

Secondary (10)

Malaria incidence among children aged 5-36 months over 24 and 36 months
Malaria incidence among children aged 3-59 months over 24 and 36 months
Malaria prevalence at peak transmission
Vaccine coverage
Occurrence of adverse events (AEs) and serious adverse events (SAEs) following R21/Matrix-M vaccination;
Show 5 moreShow less
Acceptability
Stakeholder perceptions of the feasibility on the vaccine delivery strategy in each group
Contextual and behavioural factors impeding or facilitating R21/Matrix-M vaccine uptake
Stakeholders and caregivers perceptions of the factors that enhance and/or constrain the succesful co,pletion of four doses of R21 and the key drivers of vaccination coverage
Incremental costs (per child vaccinated) and cost-effectiveness (per malaria case and separately, per DALY averted) of each vaccination strategy, calculated from a societal perspective

Arms and interventions

Control ArmNo intervention

Children aged 5-36 months will receive R21 via routine EPI vaccination (Year round in Burkina faso, or prior to the malaria season and SMC delivery in Mali)

Integrated SMC VaccinationOther

Children aged 3-59 months will receive 3-dose primary series aligned with SMC distribution in an annual campaign

Other: Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months

Sites

2 sites in 2 countries

Burkina Faso 1, Mali 1